In conclusion, JAK2/STAT3 and/or p38-MAPK signaling interference, combined with local immune potentiation, may counterbalance tumor-imposed suppression of skin DC subsets, minimizing the induction and trans-differentiation of migratory CD14+ M2-like DC with T cell suppressive characteristics, and thus set the stage for effective tumor vaccination through DC-targeted approaches. The gene discussed is JAK2; the disease is neoplasm.